Merck (MSD) Announces Friday July 24 Voluntary Licensing Agreements With Aspen Pharmacare (South Africa), Quality Chemical Industries (Uganda), and UCL Kenya in Sub-Saharan Africa Plus Aurobindo, Cipla, Emcure, and Viatris in India for Investigational Once-Monthly Oral HIV Prevention Pill MK-8527 (Alimatravir) Covering 129 Low- and Middle-Income Countries Including Every African Nation; Late-Stage Phase 3 Clinical Trial Results for Alimatravir Are Not Expected Until Late 2027
Merck (MSD) announced Friday July 24, 2026 seven voluntary, royalty-free, non-exclusive licensing agreements with generic drug manufacturers covering the investigational once-monthly oral HIV prevention pill MK-8527 (alimatravir). The licensees are Aspen Pharmacare (South Africa), Quality Chemical Industries (Uganda), and UCL Kenya in sub-Saharan Africa, plus Aurobindo, Cipla, Emcure, and Viatris in India. The territorial scope covers 129 low- and middle-income countries including every African nation. Alimatravir is an investigational late-stage once-monthly long-acting oral medicine for HIV-1 prevention, currently in Phase 3 development. Phase 3 topline results are not expected until late 2027. Alimatravir is designed to provide one month of protection from HIV-1 starting within one hour after dosing. Coverage frames the licensing structure as one of the broadest generic-access pre-approval commitments Merck has undertaken for an HIV asset. The announcement follows the April 7 STAT reporting that Merck's experimental HIV prevention pill could be made for less than $5 a year at manufacturing cost. Merck plans to file for regulatory approval in 2027-2028 with market launch dependent on Phase 3 outcome.